Decades of science on the inflammatory hypothesis of atherosclerosis translate into actionable clinical therapeutic to reduce residual CV risk3' education - Aug. 27, 2017
ESC 2017 Peter Libby, who started basic research on the role of IL-1 in atherogenesis 30 years ago, gives his perspective on the CANTOS results, including the preliminary results that hint at a reduction in cancer fatalities.
This 3-minute education provides a summary of just presented scientific data, recorded during the ESC 2017 congress. The objective is to provide a brief commentary and potential implications of these findings.
Prof. Peter Libby - Brigham and Women's Hospital, Boston, MA, USA
The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme. PACE-cme did not receive financial support for the production of this 3-minute education.